DK1131073T3 - Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme - Google Patents

Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme

Info

Publication number
DK1131073T3
DK1131073T3 DK99957321T DK99957321T DK1131073T3 DK 1131073 T3 DK1131073 T3 DK 1131073T3 DK 99957321 T DK99957321 T DK 99957321T DK 99957321 T DK99957321 T DK 99957321T DK 1131073 T3 DK1131073 T3 DK 1131073T3
Authority
DK
Denmark
Prior art keywords
treatment
ocular neovascular
neovascular diseases
staurosporine derivatives
staurosporine
Prior art date
Application number
DK99957321T
Other languages
Danish (da)
English (en)
Inventor
Romulus Kimbro Brazzell
Jeanette Marjorie Wood
Peter Anthony Campochiaro
Frances Elizabeth Kane
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1131073T3 publication Critical patent/DK1131073T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99957321T 1998-11-23 1999-11-22 Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme DK1131073T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19867798A 1998-11-23 1998-11-23
PCT/EP1999/008987 WO2000030651A1 (en) 1998-11-23 1999-11-22 Use of staurosporine derivatives for treating ocular neovascular diseases

Publications (1)

Publication Number Publication Date
DK1131073T3 true DK1131073T3 (da) 2004-02-02

Family

ID=22734344

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99957321T DK1131073T3 (da) 1998-11-23 1999-11-22 Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme

Country Status (19)

Country Link
EP (1) EP1131073B1 (id)
JP (2) JP2002530342A (id)
KR (1) KR100698449B1 (id)
CN (1) CN1172673C (id)
AT (1) ATE252387T1 (id)
AU (1) AU761092B2 (id)
BR (1) BR9915569A (id)
CA (1) CA2348890C (id)
DE (1) DE69912304T2 (id)
DK (1) DK1131073T3 (id)
ES (1) ES2211197T3 (id)
HK (1) HK1040182A1 (id)
ID (1) ID29970A (id)
IL (2) IL142757A0 (id)
NO (1) NO328085B1 (id)
NZ (1) NZ511559A (id)
PT (1) PT1131073E (id)
WO (1) WO2000030651A1 (id)
ZA (1) ZA200103925B (id)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
CA2492989C (en) * 2002-07-23 2012-11-20 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN101580515B (zh) * 2008-05-16 2011-06-08 上海医药工业研究院 一种星形孢菌素提取纯化的方法
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102924479A (zh) * 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
JPH08502033A (ja) * 1992-07-08 1996-03-05 セルトリックス ファーマシューティカルズ，インコーポレイテッド ＴＧＦ−βを用いる眼疾患の治療方法
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
WO1999045920A2 (en) * 1998-03-13 1999-09-16 Johns Hopkins University School Of Medicine The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Also Published As

Publication number Publication date
ES2211197T3 (es) 2004-07-01
WO2000030651A1 (en) 2000-06-02
JP2011088938A (ja) 2011-05-06
DE69912304D1 (de) 2003-11-27
KR20010078398A (ko) 2001-08-20
NZ511559A (en) 2004-01-30
DE69912304T2 (de) 2004-07-22
IL142757A (en) 2007-07-04
KR100698449B1 (ko) 2007-03-23
BR9915569A (pt) 2001-08-14
ATE252387T1 (de) 2003-11-15
CN1172673C (zh) 2004-10-27
ID29970A (id) 2001-10-25
EP1131073B1 (en) 2003-10-22
CA2348890C (en) 2009-05-12
NO20012490L (no) 2001-06-25
HK1040182A1 (en) 2002-05-31
AU1506600A (en) 2000-06-13
CA2348890A1 (en) 2000-06-02
JP2002530342A (ja) 2002-09-17
CN1328462A (zh) 2001-12-26
EP1131073A1 (en) 2001-09-12
IL142757A0 (en) 2002-03-10
AU761092B2 (en) 2003-05-29
PT1131073E (pt) 2004-03-31
NO20012490D0 (no) 2001-05-21
NO328085B1 (no) 2009-11-30
ZA200103925B (en) 2002-07-25

Similar Documents

Publication Publication Date Title
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
BR9811012A (pt) "uso de um composto".
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
DE69940951D1 (de) Nd wachstumshemmende mittel
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
NO20024486D0 (no) Forbedret behandling av neovaskularisering
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
DK1110554T3 (da) Medicinal præparater til behandling af öjensygdomme
DE60130872D1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
WO2000009098A3 (en) Method for treating ocular neovascular diseases
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
MY145266A (en) Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen
BR0215752A (pt) Piranoindazóis e seu uso no tratamento de glaucoma